Man Group
VNDA icon

Man Group’s Vanda Pharmaceuticals VNDA Stock Holding History

Man Group’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$940K Buy
153,557
+73,497
+92% +$480K ﹤0.01% 1878
2026
Q1 		$553K Buy
+80,060
New +$617K ﹤0.01% 2051
2025
Q2 		– Sell
-17,361
Closed -$79.7K – 2404
2025
Q1 		$79.7K Buy
+17,361
New +$80.9K ﹤0.01% 2120
2024
Q2 		– Sell
-47,730
Closed -$196K – 2288
2024
Q1 		$196K Buy
+47,730
New +$191K ﹤0.01% 2012
2023
Q3 		– Sell
-273,121
Closed -$1.52M – 1297
2023
Q2 		$1.8M Buy
+273,121
New +$1.75M 0.01% 1237
2023
Q1 		– Sell
-155,885
Closed -$1.1M – 1536
2022
Q4 		$1.15M Buy
155,885
+30,687
+25% +$299K ﹤0.01% 1279
2022
Q3 		$1.24M Buy
+125,198
New +$1.32M 0.01% 1213
2022
Q2 		– Sell
-55,318
Closed -$573K – 1316
2022
Q1 		$625K Buy
+55,318
New +$727K ﹤0.01% 1522
2021
Q2 		– Sell
-28,880
Closed -$434K – 2105
2021
Q1 		$434K Sell
28,880
-294,392
-91% -$4.77M ﹤0.01% 1519
2020
Q4 		$4.25M Sell
323,272
-21,400
-6% -$258K 0.02% 898
2020
Q3 		$3.33M Sell
344,672
-22,000
-6% -$235K 0.01% 1008
2020
Q2 		$4.2M Sell
366,672
-44,880
-11% -$508K 0.02% 756
2020
Q1 		$4.26M Buy
411,552
+119,905
+41% +$1.49M 0.03% 544
2019
Q4 		$4.79M Buy
291,647
+161,927
+125% +$2.45M 0.02% 1008
2019
Q3 		$1.72M Buy
+129,720
New +$1.81M 0.01% 1298
2019
Q2 		– Sell
-14,721
Closed -$271K – 2016
2019
Q1 		$271K Sell
14,721
-69,499
-83% -$1.58M ﹤0.01% 1828
2018
Q4 		$2.2M Sell
84,220
-111,815
-57% -$2.63M 0.01% 1174
2018
Q3 		$4.5M Sell
196,035
-108,537
-36% -$2.22M 0.02% 1054
2018
Q2 		$5.8M Sell
304,572
-212,028
-41% -$3.55M 0.02% 866
2018
Q1 		$8.71M Buy
+516,600
New +$8.65M 0.04% 554

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Man Group's VNDA Position: Q2 2026 in Review

Man Group increased its Vanda Pharmaceuticals (VNDA) stake by 92% in Q2 2026, buying an estimated $480K and bringing the position to 153,557 shares worth $940K. The position accounts for ﹤0.01% of the portfolio, ranked #1878.

Man Group first reported a position in VNDA in Q1 2018 and has held it in 20 quarters since. The position peaked at $8.71M in Q1 2018. 173 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • Man Group held 153,557 shares of Vanda Pharmaceuticals worth $940K as of Q2 2026.
  • Man Group bought 73,497 Vanda Pharmaceuticals shares in Q2 2026, an estimated $480K.
  • Vanda Pharmaceuticals made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #1878 holding.
  • Man Group first reported a position in Vanda Pharmaceuticals in Q1 2018 and has held it in 20 quarters since.
  • Man Group's Vanda Pharmaceuticals position peaked at $8.71M in Q1 2018.
  • 173 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.